![]() ![]() It gives me the flexibility to alter my treatment schedule when I need to. The first thing she said to me when I walked in the door was I love my Tablo. This individual had tried every form of dialysis possible from in-center dialysis to peritoneal dialysis to the incumbent home hemo machine. Since the third quarter marks the beginning of our home re-ramp, I wanted to start by sharing an experience I recently had visiting a patient using Tablo in her home. I am immensely proud of the impact our team has been able to make in the lives of patients in such a short period of time.īased on Q3 momentum, we are raising our fiscal year 2022 revenue guidance today to reflect our continued confidence in the strong underlying market fundamentals and demand for Tablo across our acute and home end market. What’s more just following the close of the quarter, we shift our 1 million treatment for Tablo. On the home front, the early success of our rebuilding process validated our strong relationships with home providers and patient preference for Tablo. On the acute side, we were encouraged by meaningful Tablo expansion among current customers and adoption from new customers despite lingering staffing and inflationary pressures. We are very pleased to share our third quarter 2022 results, which were marked by strong revenue growth and a home re-ramp that outpaced our expectations. ![]() Good afternoon everyone and thank you for joining us. With that, let me now turn the call over to Leslie. For a list and description of the risks and uncertainties associated with our business please refer to the Risk Factors section of Outset’s public filings, with the Securities and Exchange Commission, including our latest annual and quarterly reports. Outset assumes no obligation to update these statements. These statements relate to expectations or predictions of future events are based on our current estimates and various assumptions, and involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied. It is our intent that all forward-looking statements made during today’s call will be protected under the Private Securities Litigation Reform Act of 1995. This call is being recorded, and will be archived in the Investors section of our website. We issued a news release after the close of market today and updated our investor presentation, both of which can be found on the investor pages of. During the call, we will discuss our third quarter operational and financial results, provide an update on our outlook, and host the question-and-answer session. Here with me today are Leslie Trigg, Chair and Chief Executive Officer and Nabeel Ahmed, Chief Financial Officer. Welcome to our third quarter 2022 earnings call. Jim Mazzola: Great, thank you, and good afternoon everyone. I would now like to hand the conference over to your speaker today Jim Mazzola, Vice President of Investor Relations. Please be advised that today’s conference is being recorded. After the speakers’ presentation, there will be a question-and-answer session. At this time, all participants are in a listen-only mode. Welcome to Outset Medical Third Quarter 2022 Earnings Conference Call. Operator: Good day and thank you for standing by. Reported EPS is $-0.85 EPS, expectations were $-0.81. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |